Compare GNW & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNW | ADPT |
|---|---|---|
| Founded | 1871 | 2009 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2004 | 2019 |
| Metric | GNW | ADPT |
|---|---|---|
| Price | $8.75 | $16.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 3.2M | 1.8M |
| Earning Date | 05-02-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 325.00 | 30.77 |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $7,295,000,000.00 | $178,957,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.05 |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | ★ 5.10 |
| 52 Week Low | $5.99 | $6.26 |
| 52 Week High | $9.28 | $20.76 |
| Indicator | GNW | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 43.04 |
| Support Level | $8.84 | $14.85 |
| Resistance Level | $9.08 | $16.42 |
| Average True Range (ATR) | 0.23 | 1.09 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 56.32 | 25.25 |
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).